SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON D.C. 20549

                                   FORM 10-Q

                  QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                    For the quarter ended December 31, 2010

                         Commission File Number 0-10683

                                 HYDROMER, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)

     New Jersey                                                  22-2303576
----------------------                                       -------------------
(State of incorporation)                                     (I.R.S. Employer
                                                             Identification No.)

35 Industrial Pkwy, Branchburg, New Jersey                        08876-3424
------------------------------------------                   -------------------
  (Address of principal executive offices)                        (Zip Code)

Registrant's telephone number, including area code:             (908) 722-5000
                                                             -------------------

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

                         Common Stock Without Par Value
                                (Title of class)

   Indicate  by  check  mark  whether  the  registrant (1) has filed all reports
required  to  be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or  for  such shorter period that the
registrant was required to file such report(s), and (2) has been subject to such
filing requirements for the past 90 days. [x] Yes [ ] No

   Indicate  by  check mark whether the registrant is a large accelerated filer,
an  accelerated  filer, a non-accelerated filer, or a smaller reporting company.
Large accelerated filer [ ] Accelerated  filer [ ]Non-accelerated filer [ ]
Smaller reporting company [x]

   Indicate  by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).
Yes  [ ]           No   [x]

                 Class                        Outstanding at December 31, 2010
                 -----                        --------------------------------
                Common                                   4,772,318

























<PAGE>

                 ----------------------------------------------
                           FORWARD-LOOKING STATEMENTS

This  quarterly  report  on Form 10-Q contains forward-looking statements within
the  meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements include, among other
things,  business  strategy  and  expectations  concerning  industry conditions,
market  position,  future  operations,  margins,  profitability,  liquidity  and
capital resources. Forward-looking statements generally can be identified by the
use  of  terminology  such  as  "may,"  "will,"  "expect," "intend," "estimate,"
"anticipate" or "believe" or similar expressions or the negatives thereof. These
expectations  are based on management's assumptions and current beliefs based on
currently   available  information.  Although  the  Company  believes  that  the
expectations  reflected  in  such  statements  are  reasonable,  it  can give no
assurance that such expectations will be correct. You are cautioned not to place
undue  reliance  on these forward-looking statements, which speak only as of the
date  of  this  quarterly  report on Form 10-Q and the Company does not have any
obligation  to  update  the forward looking statements. The Company's operations
are  subject  to  a number of uncertainties, risks and other influences, many of
which  are outside its control, and any one of which, or a combination of which,
could  cause  its  actual  results  of  operations to differ materially from the
forward-looking statements.























































<PAGE>
                                 HYDROMER, INC.

                               INDEX TO FORM 10-Q
                               December 31, 2010

                                                                        Page No.
Part I  -  Financial Information

    # 1 Consolidated Financial Statements

         Balance Sheets - December 31, 2010 & June 30, 2010                  3

         Statements of Operations for the three months and six months        4
            ended December 31, 2010 and 2009

         Statements of Cash Flows for the six months ended
            December 31, 2010 and 2009                                       5

         Notes to Financial Statements                                       6

    # 2  Management's Discussion and Analysis of the Financial
             Condition and Results of Operations                             7

    # 3  Controls and Procedures                                             9


Part II  -  Other Information

    # 1  Legal Proceedings                                                  N/A

    # 2  Change in Securities                                               N/A

    # 3  Default of  Senior Securities                                      N/A

    # 4  Submission of Motion to Vote of Security Holders                   N/A

    # 5  Other Information                                                  N/A

    # 6  Exhibits                                                            9


                                 EXHIBIT INDEX

Exhibit No.     Description of Exhibit
-----------     ----------------------
31.1            SEC Section 302 Certification - CEO certification           10
31.2            SEC Section 302 Certification - CFO certification           11

32.1            Certification of Manfred F. Dyck, Chief Executive
                            Officer, pursuant to 18 U.S.C. Section 1350     12

32.2            Certification of Robert Y. Lee, Chief Financial
                            Officer, pursuant to 18 U.S.C. Section 1350     12

























<PAGE>
PART I - CONSOLIDATED FINANCIAL STATEMENTS
ITEM # 1
<TABLE>


                                       HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                                               CONSOLIDATED BALANCE SHEETS
<S>                                                                         <C>               <C>
ASSETS                                                                  December 31,        June 30,
                                                                            2010              2010
                                                                          UNAUDITED         AUDITED
Current Assets:
   Cash and cash equivalents                                          $    613,903        $    843,610
   Short-term investments                                                       -              440,000
   Trade receivables  less  allowance  for  doubtful  accounts  of
        $31,335 and $33,276 as  of December 31,  2010 and June 30,         812,999             920,252
         2010, respectively
   Inventory                                                               318,566             248,569
   Prepaid expenses                                                        150,799             227,338
   Other                                                                     1,150              15,487
------------------------------------------------------------------------------------------------------------------------------------
Total Current Assets                                                     1,897,417           2,695,256
------------------------------------------------------------------------------------------------------------------------------------

Property and equipment, net                                              2,948,957           2,988,536
Deferred tax asset, non-current                                          1,191,828           1,011,945
Intangible assets, net                                                     845,091             839,722
------------------------------------------------------------------------------------------------------------------------------------
      Total Assets                                                    $  6,883,293        $  7,535,459
------------------------------------------------------------------------------------------------------------------------------------

LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------------------------------------------------------------------------------------------------------
Current Liabilities:
         Accounts payable                                             $    266,104        $    342,030
         Accrued expenses                                                  212,892             251,276
         Current portion of capital lease                                   16,788              16,000
         Current portion of deferred revenue                                78,023              75,828
         Current portion of mortgage payable                                50,508              48,800
         Income tax payable                                                  3,891                  -
------------------------------------------------------------------------------------------------------------------------------------
      Total Current Liabilities                                            628,206             733,934
------------------------------------------------------------------------------------------------------------------------------------
Deferred tax liability                                                     283,375             318,375
Long-term portion of capital lease                                          25,677              34,716
Long-term portion of deferred revenue                                      142,977             165,813
Long-term portion of mortgage payable                                    2,742,379           2,769,036
------------------------------------------------------------------------------------------------------------------------------------
Total Liabilities                                                        3,822,614           4,021,874
------------------------------------------------------------------------------------------------------------------------------------

Stockholders' Equity
   Preferred stock - no par value, authorized 1,000,000 shares, no
        shares issued and outstanding                                        -                     -
   Common stock - no par value, authorized 15,000,000 shares;
        4,783,235 shares issued and 4,772,318 shares outstanding as
        of December 31, 2010 and June 30, 2010                           3,721,815           3,721,815
   Contributed capital                                                     633,150             633,150
   Accumulated deficit                                                  (1,288,146)           (835,240)
   Treasury stock, 10,917 common shares at cost                             (6,140)             (6,140)
------------------------------------------------------------------------------------------------------------------------------------
Total Stockholders' Equity                                               3,060,679           3,513,585
------------------------------------------------------------------------------------------------------------------------------------
Total Liabilities and Stockholders' Equity                            $  6,883,293        $  7,535,459
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
                                                  See accompanying notes











<PAGE>
<TABLE>
                                       HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                                          CONSOLIDATED STATEMENTS OF OPERATIONS
<S>                                                                    <C>                              <C>
                                                               Three Months Ended                 Six months Ended
                                                                  December 31,                      December 31,
<S>                                                            <C>              <C>             <C>              <C>
                                                               2010            2009            2010             2009
                                                            UNAUDITED        UNAUDITED       UNAUDITED         UNAUDITED
---------------------------------------------------------  -----------------------------    ------------------------------
REVENUES
   Sale of products                                       $   560,330    $      829,402   $  1,210,734     $   2,011,106
   Service revenues                                           401,068           359,491        770,389           659,283
   Royalties and Contract Revenues                            244,727           227,221        480,894           455,296
                                                           -------------    ------------    --------------   -------------
       TOTAL REVENUES
                                                            1,206,125         1,416,114      2,462,017         3,125,685
---------------------------------------------------------  -----------------------------    ------------------------------
EXPENSES
   Cost of Sales                                              321,983           627,263        748,582         1,467,457
   Operating Expenses                                       1,077,919         1,221,493      2,277,211         2,487,853
   Other Expenses                                              48,683            30,024         98,562            81,638
   Gain from Sale of Assets                                       -            (335,629)           -            (335,629)
   Benefit from Income Taxes                                  (44,504)          (49,900)      (209,432)         (226,109)
                                                           -------------    ------------    --------------   -------------
       TOTAL EXPENSES                                       1,404,081         1,493,251      2,914,923         3,475,210
---------------------------------------------------------  -----------------------------    ------------------------------
       NET LOSS                                           $  (197,956)   $      (77,137)  $   (452,906)    $    (349,525)
---------------------------------------------------------  -----------------------------    ------------------------------
       Loss Per Common Share                              $     (0.04)   $        (0.02)  $      (0.09)    $       (0.07)

Weighted Average Number of
    Common Shares Outstanding                               4,772,318         4,772,318      4,772,318         4,772,318
</TABLE>






                            See accompanying notes.

            There was no impact to earnings per share from dilutive
                  securities as the resultant would have been
                                 anti-dilutive.

































<PAGE>
<TABLE>
                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
<S>                                                                      <C>            <C>
                                                                                  Six months Ended
                                                                                     December 31,
                                                                              2010             2009
                                                                            UNAUDITED        UNAUDITED
------------------------------------------------------------------------------------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
    Net Loss                                                             $  (452,906)   $    (349,525)
    Adjustments to reconcile net loss to net cash used for
    operating activities
        Gain on Sale of Product Lines                                           -            (335,629)
        Depreciation and amortization                                        200,838          220,542
        Deferred income taxes                                               (214,883)        (227,464)
        Changes in Assets and Liabilities:
           Trade receivables                                                 107,253          350,082
           Inventory                                                         (69,997)          61,612
           Prepaid expenses                                                   63,912           54,544
           Other assets                                                       14,337          (11,706)
           Accounts payable and accrued liabilities                         (121,416)        (116,200)
           Deferred income                                                   (20,641)          12,511
           Income taxes payable                                                3,891          (73,811)
------------------------------------------------------------------------------------------------------------------------------------
              Net Cash Used in Operating Activities                         (489,612)        (415,044)

------------------------------------------------------------------------------------------------------------------------------------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Cash purchases of property and equipment                                   (66,390)      (126,436)
    Cash payments on patents and trademarks                                    (88,756)      (156,100)
    Redemption of matured short-term investments                               440,000        260,000
    Cash purchases of short-term investments                                       -         (250,000)
    Proceeds Received from the sale of Product Lines                               -          400,000
------------------------------------------------------------------------------------------------------------------------------------
              Net Cash Provided by Investing Activities                        284,854        127,464

------------------------------------------------------------------------------------------------------------------------------------
CASH FLOWS FROM FINANCING ACTIVITIES:
    Repayment of long-term borrowings                                          (24,949)       (23,282)
------------------------------------------------------------------------------------------------------------------------------------
               Net Cash Used in Financing Activities                           (24,949)       (23,282)

------------------------------------------------------------------------------------------------------------------------------------
NET DECREASE IN CASH AND CASH EQUIVALENTS:                                    (229,707)      (310,862)
Cash and Cash Equivalents at Beginning of Period                               843,610      1,585,765
------------------------------------------------------------------------------------------------------------------------------------
Cash and Cash Equivalents at End of Period                               $     613,903    $ 1,274,903
------------------------------------------------------------------------------------------------------------------------------------

Non-Cash Investing and Financing Activities:
    Note Receivable in exchange for Sale of Product Lines                                 $   400,000
</TABLE>



                            See accompanying notes.




















<PAGE>
                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY

                   Notes to Consolidated Financial Statements

In  the  opinion  of management, the accompanying unaudited financial statements
include  all adjustments (consisting of only normal adjustments) necessary for a
fair   presentation   of   the   results   for   the  interim  periods.  Certain
reclassifications  have  been  made  to  the  previous year's results to present
comparable financial statements.

Subsequent Events:
Due  to the net loss for the six months ended December 31, 2010, the Company did
not meet two mortgage covenants. A waiver has been granted by the lender for the
period.  Although a waiver was granted by the lender, there is no certainty that
future waivers would be granted.

Significant Events:
On  November  25, 2009, the Company's wholly owned subsidiary, Biosearch Medical
Products,  Inc.  ("BMPI")  sold  its  Private  Label  Jejunostomy  Catheter  and
Nasogastric   Feeding   Catheter  business  to  Forefront  Medical  Technologies
("Forefront"),  a  wholly  owned subsidiary of Vicplas International Limited - a
company  registered  in  the  Republic  of Singapore, for $800,000 in cash, half
received  upon closing in November 2009 with the balance received in March 2010.
This  sale  included  inventory  and equipment related to that business and also
calls  for the assignment of certain customer supply agreements to Forefront and
a  three year non-compete provision. A separate supply agreement for Hydromer(R)
hydrophilic coating solution used on those products was also entered between the
parties.  BMPI  continued manufacturing the products, at an agreed upon transfer
price, until Forefront completed the transition in April 2010. Accordingly, this
transaction  does  not meet the criteria of Discontinued Operations of Financial
Accounting  Standards Board Accounting Standards Codification paragraphs 205-20.
These  product  lines  sold  were  part  of  the "Medical Products" segment (see
following Segment Reporting section).

Fair Value:
Some  of the Company's financial instruments are not measured at fair value on a
recurring  basis  but are recorded at amounts that approximate fair value due to
their   liquid  or  short-term  nature,  such  as  cash  and  cash  equivalents,
receivables  and  payables. The carrying amount of the Company's note obligation
approximates  its  fair value, as the terms of the note is consistent with terms
available in the market for instruments with similar risk.

Segment Reporting:
The  Company  operates  two primary business segments. The Company evaluates the
segments  by  revenues,  total  expenses  and  earnings  before taxes. Corporate
Overhead  (primarily  the  salaries  and  benefits of senior management, support
services  (Accounting,  Legal,  Human Resources and Purchasing) and other shared
services  (building  maintenance and warehousing) are excluded from the business
segments  as to not distort the contribution of each segment. These segments are
the  lowest  levels for which identifiable cash flows are largely independent of
the cash flows of other assets and liabilities.

The results for the six months ended December 31, by segment are:
<TABLE>
         <S>                                      <C>               <C>              <C>            <C>
                                                  Polymer           Medical          Corporate
                                                  Research          Products         Overhead       Total
         2010
         Revenues                                  $    1,755,262  $        706,755  $              $     2,462,017
         Expenses                                      (1,647,639)         (647,048)     (829,668)       (3,124,355)
                                                  ---------------- ----------------- -------------- ----------------
              Pre-tax Income (Loss)                $      107,623  $         59,707  $   (829,668)  $      (622,338)
                                                  ================ ================= ============== ================
         -----------------------------------------------------------------------------------------------------------
         2009 (excludes the Sale of Product
         Lines)
         Revenues                                  $    1,884,565   $     1,241,120                 $     3,125,685
         Expenses                                      (1,925,793)       (1,315,354) $    (795,801)      (4,036,948)
                                                  ---------------- ----------------- -------------- ----------------
              Pre-tax Income (Loss)                $      (41,228)  $       (74,234) $    (795,801) $      (911,263)
                                                  ================ ================= ============== ================
</TABLE>
Geographic revenues were as follows for the six months ended December 31,

                                                             2010      2009
                                                             ----      ----
                                 Domestic                     67%       73%
                                 Foreign                      33%       27%
<PAGE>
ITEM #2

                  MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

The  Company's revenues for the quarter ended December 31, 2010 were $1,206,125,
$209,989  or  14.8%  lower  than the $1,416,114 for the same period the previous
year.  Revenues  are  comprised of the sale of Products and Services and Royalty
and Contract payments.

      Product  sales  were  $560,330  for the quarter ended December 31, 2010 as
      compared  to  $829,402  for  the  same  period the year before, a $269,072
      (32.4%) decrease; lower primarily due to the divestiture of medical device
      product  lines  in  February  and  November 2009. Sales from these product
      lines during the quarter ended December 31, 2009 totaled $191,609. For the
      six month period ended December 31, 2010, product sales were $1,210,734 as
      compared  with  $2,011,106  or $800,372 (39.8%) lower than the same period
      the  year  before.  Sales  from  the  divested product lines accounted for
      $707,454  of  the  difference.  Sales timing differences accounted for the
      remainder of the period-to-period variances.

      Services  revenues  for  the  three  months  ended  December  31, 2010 was
      $401,068  or  $41,577  higher  (11.6%) than the $359,491 the corresponding
      period  the  year  before.  Services  revenues  for  the  six months ended
      December  31,  2010  was  $770,389  or  $111,106  higher  (16.9%) than the
      $659,283  the  corresponding  period the year before. Increased demand for
      our  services,  primarily  on guidewires and PTCA catheters, accounted for
      the increase.

      Royalty  and Contract revenues include royalties received and the periodic
      recurring  payments  from  license,  stand  still and other agreements for
      other than product and services. Included in Royalty and Contract revenues
      are revenues from support and supply agreements. Some of the royalties and
      support  fees  are  based on the net sales of the final item (to which the
      Hydromer technology is applied to) and are subject to the reporting of our
      customers.  For  the quarter ended December 31, 2010, Royalty and Contract
      revenues  were  $244,727, compared to $227,221 the same period a year ago.
      For  the six months ended December 31, 2010, Royalty and Contract revenues
      were  $480,894,  $25,598 or 5.6% higher than the previous year's period of
      $455,296.  We  continue  entering  into  new  Royalty and Contract revenue
      agreements,  some which begin with our customer's first commercial sale of
      their product. Once online, including with the commercialization of one of
      our  hydrogel  technologies, we anticipate a doubling of this revenue line
      within the next few years.

      Discounting  the lower revenues from the divested product lines, we have a
      modest  gain  in  total revenues against the prior year despite the timing
      difference.  We  look  to  realize the timing differences sales within the
      next  quarter  or  two  and  to further grow revenues, particularly in our
      T-HEXX(R)  Animal  Health  business  where  a majority of our research and
      development during the past two years has been focused upon.

Total  Expenses  for  the  quarter  ended  December  31, 2010 were $1,404,081 as
compared  with  $1,493,251  the year before, a 6.0% decrease. For the six months
ended  December  31,  2010,  total  expenses  were  $2,914,923  as compared with
$3,475,210  the  same period the year before, or 16.1% better. Reducing expenses
for  the  three  months  ended  December  31, 2009 was the gain from the sale of
product  lines  of $335,629. When excluding the gain from sale of product lines,
total  expenses  for  the  three  months ended December 31, 2009 would have been
$1,828,880  or  with  the current quarter $424,800 (23.2%) better and $3,810,839
for  the six months period the year before or with the current year period 23.5%
better ($895,916).

      For  the quarter ended December 31, 2010, the Company's Cost of Goods Sold
      was  $321,983  as compared with $627,263 the year prior, lower by $305,281
      or  48.7%.  The  Cost  of  Goods Sold attributed to the sold product lines
      approximated $253,000 in the December 2009 quarter. Cost of Goods Sold for
      the  six  month  period  was  $748,582 or $718,875 better (49.0%) than the
      prior year's $1,467,457, which included approximately $699,000 relating to
      the divested product lines.






<PAGE>
      Operating expenses were $1,077,919 for the quarter ended December 31, 2010
      as  compared  with $1,221,493 the year before, lower by $143,574 or 11.8%.
      For  the  six  month  period, Operating expenses were $2,277,211 this year
      compared  with  $2,487,853  the  year  before,  an improvement of $210,642
      (8.5%).  The  prior year period included approximately $48,000 in one-time
      legal  fees  relating  to  the right to market clearance work. Most of the
      reduction  to  Operating  expenses  related  to  a  lower  staffing level,
      including  in  part  due  to the divestiture of the medical device product
      lines,  as  offset  by  increases  in  marketing and sales expenses in our
      T-HEXX  Animal  Health  business (added international tradeshow promotions
      and related travel and marketing expenditures).

      Interest  expense,  interest income and other income are included in Other
      Expenses.  Interest  expense  (on  the  mortgage) for the six months ended
      December  31,  2010  and  December  31,  2009  were  $98,550 and $100,237,
      respectively.  Interest  income  for the six month periods were $4,408 for
      the 2010 period as compared with $18,589 for the 2009 period, lower due to
      a lower earnings base.

A  net  loss  of  $197,956  ($0.04  per share) is reported for the quarter ended
December  31,  2010  as  compared to a net loss of $77,137 ($0.02 per share) the
year before. For the six months ended  December 31, 2010, a net loss of $452,906
($0.09 per  share) is reported compared against  a  net loss  of $349,525 ($0.07
per share) for  the  same period year before.

      Despite having $663,668 lower in sales this year-to-date, all attributable
      to  the  sale  of  the  medical  device  product lines, expense reductions
      brought  the  pre-tax base of the two periods more on par (a difference of
      $86,704 with the 2009 period gain on sale of assets reducing expenses that
      period  or an improvement of $248,925 when excluding the gain). However, a
      change  to the allocation rules on taxable income for NJ State reduced the
      effective  tax  rate  and  Income  Tax  Benefit, but more so, impacted the
      Deferred  Tax  Asset  and Deferred Tax Liability balances. For the quarter
      ended  December  31, 2010, the total effect was approximately $74,000. Had
      this  tax  change  not occur, the net loss for the quarter would have been
      lower  by  approximately  $74,000 making the three and six month's results
      about  that  of  the  prior year. In addition, when excluding the one-time
      gain from the sale of assets, there would be an improvement in this year's
      reported  results  over  the  prior  year. The Company expects to continue
      improvements   to  its  results  coming  from  increasing  revenues  while
      maintaining  its  expense base. The increase in revenues is anticipated to
      come  from growth in existing business as well as new sales (new customers
      and new products such as the Dragonhyde(R) Hoof Bath Concentrates).

Financial Condition

Working  capital  decreased  $692,111  during  the six months ended December 31,
2010.

Net  operating  activities  used  $489,612  during  the  six  month period ended
December 31, 2010.

      The  net  loss,  as  adjusted  for  non-cash  expenses of depreciation and
      amortization  and  deferred  income  taxes, used $466,951 in cash. The net
      change  in  other  operating  assets and liabilities used $22,661 in cash,
      with  the  primarily activities the collection of trade receivables offset
      by the reduction in accounts payable and accrued liabilities.

Investing  activities  provided  $284,854  and financing activities used $24,949
during the six months ended December 31, 2010.

      Investing  activities  for the six months ended December 31, 2010 included
      $66,390  for capital expenditures and $88,756 towards the Company's patent
      estate.  $440,000 in short-term investments matured and was converted into
      cash.  Reported  under  Financing  activities  was  the  repayment  of the
      principal portion of the mortgage.

We  expect  a  turnaround  in  our  reported  results within the next few years,
replacing  the  lost  income  (from  the  cancellation of the $100,000 per month
Supply  and  Support  Agreement (in January 2009 which was replaced by a $35,000
per  month  agreement)  and  from the sale of medical device product lines) with
revenue  growth  and  new  revenues  from  new customers and new products, while
controlling the expenses.





<PAGE>
ITEM # 3

Disclosure Controls and Procedures

   As  of  the  period  covered  by  this  report,  the  Company  carried out an
evaluation,  under the supervision and with the participation of our management,
including  the  Chief  Executive  Officer  and President and the Chief Financial
Officer,  of  the  effectiveness  of  the design and operation of the disclosure
controls and procedures.

    Based  upon this evaluation, our Chief Executive Officer and Chief Financial
Officer  concluded  that,  our disclosure controls and procedures were effective
and  that there were no changes to our Company's internal control over financial
reporting  that  have materially affected, or is reasonably likely to materially
affect the Company's internal control over financial reporting during the period
covered by the Company's quarterly report.

PART II - OTHER INFORMATION

   The Company operates entirely from its sole location at 35 Industrial Parkway
in  Branchburg,  New  Jersey,  an owned facility secured by a mortgage through a
bank.

   The  existing  facility will be adequate for the Company's operations for the
foreseeable future.

ITEM # 6. Exhibits

       Exhibit No.    Description
          31.1        Rule 13a-14(a) Certification of Chief Executive Officer
                      and President
          31.2        Rule 13a-14(a) Certification of Vice President of Finance
                      and Chief Financial  Officer
          32.1        Section  1350  Certification of Chief Executive Officer
                      and Chairman, President
          32.2        Section 1350 Certification of Chief Financial Officer and
                      Vice President of Finance





                                   SIGNATURES

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on his behalf by the
undersigned thereunto duly authorized.

                                                  HYDROMER, INC.
                                                  /s/ Robert Y. Lee, VP
                                                  --------------------------
                                                  Robert Y. Lee
                                                  Principal Accounting Officer &
                                                  Chief Financial Officer



DATE: February 22, 2011




















<PAGE>
                                  EXHIBIT 31.1

I, Manfred F. Dyck, certify that:

1.      I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2.      Based on my knowledge, this quarterly report does not contain any untrue
        statement  of a material fact or omit to state a material fact necessary
        to  make  the statements made, in light of the circumstances under which
        such  statements  were  made,  not misleading with respect to the period
        covered by this quarterly report;

3.      Based  on  my  knowledge,  the financial statements, and other financial
        information  included  in  this  quarterly report, fairly present in all
        material  respects  the  financial  condition, results of operations and
        cash  flows  of  the registrant as of, and for, the periods presented in
        this quarterly report;

4.      The  registrant's  other  certifying officer, Mr. Robert Y. Lee and I am
        responsible  for  establishing  and  maintaining disclosure controls and
        procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and  internal  control  over financial reporting (as defined in Exchange
        Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5.      The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
        disclosed,  based  on  our  most  recent evaluation, to the registrant's
        auditors  and the audit committee of registrant's board of directors (or
        persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6.      The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
        indicated  in  this  quarterly  report  whether  there  were significant
        changes   in   internal   controls   or  in  other  factors  that  could
        significantly  affect  internal  controls  subsequent to the date of our
        most  recent evaluation, including any corrective actions with regard to
        significant deficiencies and material weaknesses.

Date: February 22, 2011

/s/ Manfred F. Dyck
--------------------------------------
Manfred F. Dyck, President and CEO

<PAGE>
                                  EXHIBIT 31.2

I, Robert Y. Lee, certify that:

1.      I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2.      Based on my knowledge, this quarterly report does not contain any untrue
        statement  of a material fact or omit to state a material fact necessary
        to  make  the statements made, in light of the circumstances under which
        such  statements  were  made,  not misleading with respect to the period
        covered by this quarterly report;

3.      Based  on  my  knowledge,  the financial statements, and other financial
        information  included  in  this  quarterly report, fairly present in all
        material  respects  the  financial  condition, results of operations and
        cash  flows  of  the registrant as of, and for, the periods presented in
        this quarterly report;

4.      The  registrant's other certifying officer, Mr. Manfred F. Dyck and I am
        responsible  for  establishing  and  maintaining disclosure controls and
        procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and  internal  control  over financial reporting (as defined in Exchange
        Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5.      The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
        have disclosed, based on our most recent evaluation, to the registrant's
        auditors  and the audit committee of registrant's board of directors (or
        persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6.      The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
        have  indicated  in this quarterly report whether there were significant
        changes   in   internal   controls   or  in  other  factors  that  could
        significantly  affect  internal  controls  subsequent to the date of our
        most  recent evaluation, including any corrective actions with regard to
        significant deficiencies and material weaknesses.

Date: February 22, 2011

/s/Robert Y. Lee ,VP
--------------------------------------
Robert Y. Lee, Vice President of Finance and CFO

<PAGE>
                                  EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Manfred  F.  Dyck,  certify,  pursuant to 18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Hydromer, Inc. on Form 10-Q for the six months ended December 31, 2010
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: February 22, 2011                            By:  /s/ Manfred F. Dyck
                                                       ------------------------
                                                        Manfred F. Dyck
                                                        Chairman, President and
                                                        Chief Executive Officer


--------------------------------------------------------------------------------

                                  EXHIBIT 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Robert  Y.  Lee,  certify,  pursuant  to  18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Hydromer, Inc. on Form 10-Q for the six months ended December 31, 2010
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: February 22, 2011                         By:  /s/ Robert Y. Lee, VP
                                                    ------------------------
                                                     Robert Y. Lee
                                                     Chief Financial Officer and
                                                     Vice President of Finance